Skip to content
AnalystLens

Halozyme Therapeutics Annual Report, Year Ended Dec 31, 2022

Filing Date
Filed February 21, 2023
Period End
December 31, 2022
Security
HALO
One revenue dollarkept$0.31
In the record · 2016–202610-K1110-Q328-K140

HALO filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 140 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Feb ’20Feb ’20
  3. Material agreement8-K · Apr ’22Apr ’22
  4. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 10-K filed February 21, 2023. Cited figures are marked; the original filing is the authoritative source.

Halozyme Therapeutics, Inc. describes itself as a biopharma technology platform company whose proprietary enzyme, rHuPH20, facilitates subcutaneous delivery of injected drugs and fluids through its ENHANZE technology, licensed to partners including Roche, Takeda, Janssen, argenx, BMS and others.

In 2022 total revenues were $660.1 milliona, up from $443.3 million in 2021, driven by royalties of $360.5 million (versus $203.9 million) and product sales, net of $191.0 million (versus $104.2 million). Net income was $202.1 million, or $1.44 per diluted share, compared with $402.7 million in 2021, which included a $154.2 million income tax benefit from the release of a valuation allowance; 2022 included $46.8 million of income tax expense. The company acquired Antares Pharma, Inc. on May 24, 2022 for total purchase consideration of $1,045.7 million, adding auto-injector technology and the proprietary products XYOSTED, TLANDO and NOCDURNA.

Antares represented 17% of 2022 total revenues and 9% of total assets. Operating cash flow was $240.1 millionb, and cash, cash equivalents and marketable securities totaled $362.8 million at year-end.

Total indebtedness was $1,506.1 millionc net of debt discount, including convertible notes with aggregate principal of $1,538.5 million, and the company stated it expects its cash to fund operations for at least the next twelve months. Investors should weigh the company's heavy reliance on ENHANZE collaborations, the leverage added by the 2028 convertible notes and 2022 credit facility, a cash-settlement obligation on convertible conversions that could reduce working capital, and the company's ongoing share repurchase program, under which 8.4 million shares had been repurchased for $350.0 million through December 31, 2022.

Key Highlights

  1. Total revenues rose to $660.1 million in 2022 from $443.3 million in 2021, with royalties of $360.5 million and product sales, net of $191.0 million.
  2. Net income was $202.1 million ($1.44 diluted EPS) in 2022, versus $402.7 million in 2021, which benefited from a $154.2 million income tax benefit.
  3. Acquisition of Antares Pharma, Inc. for $1,045.7 million on May 24, 2022 added auto-injector technology and the XYOSTED, TLANDO and NOCDURNA products; Antares contributed 17% of 2022 revenues.
  4. Total convertible notes principal was $1,538.5 million at December 31, 2022, including the 1.00% notes due 2028 issued in August 2022 for $720.0 million.
  5. Cash, cash equivalents and marketable securities were $362.8 million, and operating cash flow was $240.1 million in 2022.
  6. Revolving credit facility was increased to $575 million and left undrawn at year-end; the 2024 convertible notes were classified as a current liability because the conditional conversion feature was triggered.
  7. Second share repurchase program of up to $750.0 million; 8.4 million shares repurchased for $350.0 million through December 31, 2022.

Follow one dollar

Of each $1.00 of revenue in FY2022, Halozyme Therapeutics kept $0.31.

  1. Revenue$660.1M100.0%
  2. Cost of revenue−$139.3M21.1%
  3. Gross profit$520.8M78.9%
  4. Operating costs−$253.3M38.4%
  5. Operating income$267.5M40.5%
  6. Interest, other & tax−$65.4M9.9%
  7. Net income$202.1M30.6%
Computed from 10-KFY2022filed February 21, 2023Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Where FY2022 revenue went

$660.1M
  • Net income: $202.1M, 31% of revenue
  • SG&A: $143.5M, 22% of revenue
  • Cost of revenue: $139.3M, 21% of revenue
  • R&D: $66.6M, 10% of revenue
  • Other operating costs: $43.1M, 6.5% of revenue
  • Interest, other & tax: $65.4M, 9.9% of revenue

Kept 31% as net income

Full revenue history →

Financial Statements

FY2022 against FY2021

Line itemFY2022FY2021Change
Revenue$660.12M$443.31M+48.9%
Cost of Revenue$139.30M$81.41M+71.1%
Gross Profit$520.81M$361.90M+43.9%
R&D Expenses$66.61M$35.67M+86.7%
SG&A Expenses$143.53M$50.32M+185.2%
Operating Expenses$392.58M$167.41M+134.5%
Operating Income$267.53M$275.90M−3.0%
Interest Expense$16.95M$7.53M+125.2%
Net Income$202.13M$402.71M−49.8%
EPS (Basic)$1.48$2.86−48.3%
EPS (Diluted)$1.44$2.74−47.4%
Shares Outstanding (Basic)136.84M140.65M−2.7%
Shares Outstanding (Diluted)140.61M146.80M−4.2%

Frequently Asked Questions

  1. What drives Halozyme's revenue?

    Royalties from ENHANZE partner products were the largest source at $360.5 million in 2022, up from $203.9 million in 2021. The filing attributes the increase mainly to sales uptake of DARZALEX FASPRO by Janssen and Phesgo by Roche, plus new device royalty revenue from Antares. Product sales, net of $191.0 million and revenues under collaborative agreements of $108.6 million made up the rest.

  2. Why did net income fall in 2022 compared with 2021?

    2021 net income included a $154.2 million income tax benefit from releasing the valuation allowance on deferred tax assets. In 2022 the company recorded $46.8 million of income tax expense. Operating income was $267.5 million in 2022 versus $275.9 million in 2021, and SG&A rose to $143.5 million, mainly due to one-time Antares acquisition costs.

  3. How much debt does Halozyme carry and when is it due?

    Consolidated indebtedness, net of debt discount, was $1,506.1 million at December 31, 2022, including $13.5 million of 2024 Convertible Notes, $805.0 million of 2027 Convertible Notes and $720.0 million of 2028 Convertible Notes in principal terms. The 2024 notes were called for redemption in March 2023 with a $13.5 million cash payment. The 2022 Credit Agreement's term loan was repaid in August 2022, and the revolving facility was undrawn at year-end.

  4. What risks does the filing highlight for investors?

    Key risks include dependence on ENHANZE, where an adverse development for rHuPH20 could substantially affect multiple areas of the business; reliance on partners to reach development and regulatory milestones; reliance on contract manufacturers for bulk rHuPH20; and the need to raise capital in the future. Conversion of the convertible notes could dilute stockholders or require cash settlement, and the company noted its stock price has been volatile, with a 2022 range of $31.36 to $59.46.